Berlin-based radiation and medical technology firm Eckert & Ziegler reported solid first-half 2025 results, with revenue rising 2% to €148.8 million and adjusted operating profit climbing 9% to €35.4 million. Net profit surged 19% to €21.4 million, driven by robust performance in its medical segment, where sales jumped from €69.7 million to €80.5 million. However, the Isotope Products division saw a 10% decline to €68.3 million, attributed to seasonal shifts and product mix changes. Despite confirming ambitious full-year targets—including an 8% revenue increase to €320 million and a 20% rise in adjusted operating profit to €78 million—the stock fell over 3%, suggesting investor skepticism about growth sustainability or already-priced expectations.
Cyberattack Impact Overcome
The company successfully recovered from a February cyberattack that temporarily disrupted production of its critical gallium generators. The rebound supported confidence in its second-half outlook, with management emphasizing operational resilience. While the medical segment remains the core growth driver, market reaction highlights lingering concerns over segment imbalances and external challenges.
Ad
Eckert & Ziegler Stock: Buy or Sell?! New Eckert & Ziegler Analysis from February 6 delivers the answer:
The latest Eckert & Ziegler figures speak for themselves: Urgent action needed for Eckert & Ziegler investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 6.
Eckert & Ziegler: Buy or sell? Read more here...
